Elutia Inc.
ELUT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708527
No open-market purchases or sales by Elutia Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Elutia Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- −1 vs. Q4 2022
- Shares held
- 2.78M
- −1.56M (−35.9%) vs. Q4 2022
- Total value
- $4.20M
- −$14.2M (−77.2%) vs. Q4 2022
- New holders
- 4
- 7 more added
- Sold out
- 5
- 4 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELUT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 39 | $13.8M |
| Q1 2026 | 35 | $16.0M |
| Q4 2025 | 33 | $11.1M |
| Q3 2025 | 31 | $16.1M |
| Q2 2025 | 28 | $34.4M |
| Q1 2025 | 31 | $43.6M |
| Q4 2024 | 32 | $49.3M |
| Q3 2024 | 29 | $46.7M |
| Q2 2024 | 26 | $44.5M |
| Q1 2024 | 22 | $17.9M |
| Q4 2023 | 24 | $14.9M |
| Q3 2023 | 21 | $9.20M |
| Q2 2023 | 19 | $7.23M |
| Q1 2023 | 18 | $4.20M |
| Q4 2022 | 19 | $18.4M |
| Q3 2022 | 17 | $24.0M |
| Q2 2022 | 17 | $23.6M |
| Q1 2022 | 17 | $19.4M |
| Q4 2021 | 15 | $19.8M |
| Q3 2021 | 17 | $13.2M |
| Q2 2021 | 24 | $19.7M |
| Q1 2021 | 31 | $23.5M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Elutia Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Birchview Capital, LP | 1,655,184 | $2.50M | 1.96% | +140,000+9.2% | Added |
| Perkins Capital Management Inc | 275,329 | $416.0K | 0.39% | +16,250+6.3% | Added |
| Vanguard Group Inc | 248,492 | $375.2K | 0.00% | +35,028+16.4% | Added |
| Alyeska Investment Group, L.P. | 214,343 | $323.7K | 0.00% | −35,657−14.3% | Reduced |
| Prosight Management, LP | 196,443 | $296.6K | 0.14% | +11,429+6.2% | Added |
| Knollwood Investment Advisory, LLC | 58,962 | $89.0K | 0.03% | 00.0% | Unchanged |
| Brown Advisory Inc | 32,887 | $49.7K | 0.00% | −197,780−85.7% | Reduced |
| Indie Asset Partners, LLC | 26,500 | $40.0K | 0.05% | +26,500 | New |
| Renaissance Technologies LLC | 21,916 | $33.0K | 0.00% | +21,916 | New |
| Jane Street Group, LLC | 19,042 | $28.8K | 0.00% | +19,042 | New |
| Geode Capital Management, LLC | 14,112 | $21.3K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 10,151 | $15.3K | 0.00% | +330+3.4% | Added |
| Tower Research Capital LLC (TRC) | 5,134 | $8.00K | 0.00% | +4,170+432.6% | Added |
| Morgan Stanley | 1,260 | $1.90K | 0.00% | −1,702−57.5% | Reduced |
| US Bancorp | 625 | $944 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 500 | $755 | 0.00% | −551−52.4% | Reduced |
| Wells Fargo & Company | 56 | $85 | 0.00% | +17+43.6% | Added |
| WealthPLAN Partners, LLC | 34 | $51 | 0.00% | +34 | New |
| Endurant Capital Management LP | 0 | $0 | 0.00% | −1,259,544−100.0% | Sold out |
| Platinum Investment Management Ltd | 0 | $0 | 0.00% | −188,181−100.0% | Sold out |
| Pentwater Capital Management LP | 0 | $0 | 0.00% | −125,000−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −24,900−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −24−100.0% | Sold out |